Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipratropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.98 |
| ▸ | MEN1 | O00255 | 3/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.98 |
| ▸ | BLM | P54132 | 5/20 | 0.80 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipratropium SCHEMBL16762661 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3853 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL6854301 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL30987857 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL6854302 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3852 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3854 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3299299 | 0.99 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL22077027 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL6553361 | 0.99 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 605 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-3319936-B1 | BRIDGE LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES | HANGZHOU DAC BIOTECH CO LTD (CN) | 2025-12-17 | — | — | EP | claimed |
| EP-3452152-B1 | A DROPLET DELIVERY DEVICE FOR GENERATING AND DELIVERING DROPLETS TO THE PULMONARY SYSTEM | PNEUMA RESPIRATORY INC (US) | 2025-07-02 | — | — | EP | claimed |
| EP-3384909-B1 | COMBINATION OF OXYMETAZOLINE AND IPRATROPIUM IN TOPICAL NASAL APPLICATION FOR THE TREATMENT OF A COUGH | CORTES BORREGO PABLO (MX) | 2024-12-25 | — | — | EP | claimed |
| EP-4126138-B1 | AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS | INVOX BELGIUM NV (BE) | 2024-10-16 | — | — | EP | claimed |
| EP-4021483-B1 | BOTULINUMTOXIN FOR USE IN A METHOD FOR PREVENTING HUMAN GLANDS FROM RADIATION DAMAGE | Merz Therapeutics GmbH (DE) | 2024-09-25 | — | — | EP | claimed |
| WO-2024189252-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S.A. (ES) | 2024-09-19 | — | — | WO | claimed |
| EP-3470430-B1 | ANTIBODY FOR BINDING TO INTERLEUKIN 4 RECEPTOR | SUZHOU CONNECT BIOPHARMACEUTICALS LTD (CN) | 2024-08-28 | — | — | EP | claimed |
| EP-2104490-B2 | MICRONISED PARTICLES OF LOW-DOSAGE STRENGTH ACTIVE AGENTS FOR POWDER FORMULATIONS FOR INHALATION | CHIESI FARM SPA (IT) | 2024-06-26 | — | — | EP | claimed |
| EP-3982923-B1 | CONTINUOUS PROCESS FOR THE PREPARATION OF ANTICHOLINERGIC DRUGS | HOVIONE SCIENTIA LTD (IE) | 2024-05-15 | — | — | EP | claimed |
| EP-3624771-B1 | METHOD OF MAINTAINING A WATER LEVEL IN A PRESSURIZED AEROSOL CANISTER. | KINDEVA DRUG DELIVERY LP (US) | 2023-11-15 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-1809243-B2 | AEROSOL SUSPENSION FORMULATIONS CONTAINING TG 227 EA AS A PROPELLANT | BOEHRINGER INGELHEIM INT (DE) | 2022-06-08 | — | — | EP | claimed |
| WO-2026060453-A1 | IPRATROPIUM DELIVERY COMPOSITIONS, DEVICES AND METHODS | SOLSTICE ADVANCED MATERIALS US, INC. (US) | 2026-03-19 | — | — | WO | disclosed |
| WO-2026057872-A1 | INHALABLE COMPOSITIONS | INVOX BELGIUM NV (BE) | 2026-03-19 | — | — | WO | disclosed |
| WO-2026011141-A1 | COMPOSITIONS, DEVICES AND METHODS FOR RESPRITORY DELIVERY OF ACTIVE PHARMACEUTICAL INGREDIENTS | HONEYWELL INTERNATIONAL INC. (US) | 2026-01-08 | — | — | WO | disclosed |
| WO-2005116037-A1 | PURINE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005095328-A1 | CHEMICAL PROCESS AND NEW CRYSTALLINE FORM | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005005452-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005005451-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |